Flow Cytometric Assessment of TRBC1 Expression for the Diagnosis of T-Cell Lymphoma: Clinical Utility and Pitfalls Related to T-Cell Clones of Uncertain Significance.

Background: T-cell receptor constant beta chain 1 (TRBC1) has emerged as a potential clonal marker for T-cell lymphoma. This study evaluated TRBC1 expression using flow cytometry in healthy individuals and various clinical specimens, assessing its clinical utility in the diagnosis of T-cell lymphomas.

Methods: Flow cytometric analysis was performed on peripheral blood specimens from 20 healthy individuals and 186 clinical specimens (116 bone marrow aspirates, 18 peripheral bloods, 52 body fluids) from 177 patients for the exclusion or differential diagnosis of T-cell lymphoma using a panel of nine monoclonal antibodies: CD45, CD3, CD4, CD8, CD56, CD2, CD5, CD7, and TRBC1.

Characterization of an Enterococcus sp. SMC-9 strain isolated from bile of a patient with cholangitis.

The genus Enterococcus is increasingly recognized for its involvement in various human infections, with several species known to be pathogenic. This study characterized Enterococcus sp. SMC-9, isolated from bile of a patient with cholangitis, and compared its characteristics with those of Enterococcus montenegrensis CoE-012-22T, recently isolated from dried beef sausage.

Rare Case of Germline GATA2-Deficiency With Merkel Cell Carcinoma and Acute Myeloid Leukemia.

Background: Germline GATA2-deficiency usually manifests as immunodeficiencies and myeloid neoplasms and sometimes with dermatological diseases, including warts, panniculitis, and skin cancers.

Case: We report a 36-year-old woman with germline GATA2-deficiency who developed Merkel cell carcinoma followed by acute myeloid leukemia. Molecular analysis revealed a germline GATA2 S447R variant, not reported from the previous reported case, suggesting a potential association with Merkel cell carcinoma.

Guide to Rho(D) Immune Globulin in Women With Molecularly Defined Asian-type DEL (c.1227G>A).

Rh hemolytic disease of the fetus and newborn is a potential risk for D-negative mothers who produce anti-D during pregnancy, which can lead to morbidity and mortality in subsequent pregnancies. To prevent this hemolytic disease, Rho(D) immune globulin (RhIG) is generally administered to D-negative mothers without anti-D at 28 weeks of gestation and shortly after delivery. However, current guidelines suggest that pregnant mothers with molecularly defined weak D types 1, 2, 3, 4.